CCP

Cambridge Cancer Pharmaceuticals (CCP) is a UK-based biotechnology company focused on developing next-generation precision oncology therapeutics. The company specializes in targeting difficult-to-treat cancers by modulating key protein-protein interactions and signaling pathways, such as the p53-MDM2 axis and KRAS mutations. CCP leverages its expertise in medicinal chemistry and cancer biology to design small molecules that restore tumor suppression or inhibit oncogenic drivers. Their current pipeline is primarily in the discovery and pre-clinical stages, aiming to address significant unmet needs in solid and liquid tumors.